Sponsor

Clinical trials sponsored by Boehringer Ingelheim

Active studies whose public registry record names Boehringer Ingelheim as lead sponsor.

11active studies

6recruiting now

16countries represented

528largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated SteatohepatitisCondition

Survodutide, Placebo matching survodutideTreatment

Argentina, Australia445 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT06632457See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver FibrosisCondition

Survodutide, PlaceboTreatment

Argentina, Australia528 locations

Boehringer IngelheimSponsor

Updated 2026-08-21 · NCT06632444See eligibility →

Recruiting nowPhase 1

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Healthy, ObesityCondition

Formulation A, Formulation B6Treatment

United Kingdom1 locations

Boehringer IngelheimSponsor

Updated 2026-07-30 · NCT07407348See eligibility →

Recruiting nowPhase 1

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Healthy, ObesityCondition

BI 3034701, PlaceboTreatment

Japan3 locations

Boehringer IngelheimSponsor

Updated 2026-07-24 · NCT07693231See eligibility →

Opening soonPhase 1

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity

Overweight, ObesityCondition

BI 3034701, PlaceboTreatment

Germany1 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754474See eligibility →

Opening soonPhase 1

A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight

HealthyCondition

BI 3034701 (C-14)Treatment

Locations pending0 locations

Boehringer IngelheimSponsor

Updated 2026-08-19 · NCT07708493See eligibility →

Opening soonPhase 1

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

Healthy, ObesityCondition

Survodutide formulation A, Survodutide formulation B2Treatment

Germany1 locations

Boehringer IngelheimSponsor

Updated 2026-08-18 · NCT07768813See eligibility →

Active, not recruitingPhase 1

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

ObesityCondition

BI 456906, SemaglutideTreatment

Netherlands1 locations

Boehringer IngelheimSponsor

Updated 2026-09-02 · NCT05202353See eligibility →

Active, not recruitingPhase 1

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

ObesityCondition

Survodutide, SemaglutideTreatment

United States2 locations

Boehringer IngelheimSponsor

Updated 2026-05-12 · NCT06745284See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.